Bio-Rad Laboratories BIO Increase Decrease In Deferred Liabilities

Other financials

Revenue$592.1M+1.1%

Gross profit$309.4M+1.1%

Operating income$34.1M+43.9%

Net income-$527.1M-924%

EPS (diluted)-$19.55-954%

Cash & equivalents$509.0M-2.7%

Total debt$987.3M-28.4%

Total equity$6.9B+2.6%

Total assets$9.8B+2.8%

Operating cash flow$108.1M-16.8%

CapEx$30.0M-12.8%

Free cash flow$78.1M-18.2%

Market cap$7.56B+10.3%

Enterprise value$8.04B+4.2%

P/E44.8×—

P/S2.9×+0.2×

Gross margin51.9%-1.6pp

Operating margin8.8%-3.1pp

Net margin6.5%+3.4pp

FCF margin13.8%-0.2pp

Return on equity2.5%+1.3pp

Debt / equity0.1×-0.1×

Current ratio3.2×-2.8×

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredLiabilities.

The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Bio-Rad Laboratories's increase decrease in deferred liabilities?: Bio-Rad Laboratories (BIO) reported increase decrease in deferred liabilities of -$10.6M in Q1 2026.
How has Bio-Rad Laboratories's increase decrease in deferred liabilities changed year-over-year?: Bio-Rad Laboratories's increase decrease in deferred liabilities increased by 3.6% year-over-year, from -$11M to -$10.6M.